Literature DB >> 23100993

L-asparaginase induced fatal cortical venous thrombosis in acute lymphoblastic leukemia.

Sanju Cyriac1, T G Sagar, Karpurmath V Shashidhar.   

Abstract

L-asparaginase has become an integral part in the treatment of acute lymphoblastic leukemia. The major worry of using L-asparaginase is thromboembolism. The case presented here is a 21-year-old lady who developed fatal cortical venous thrombosis during induction phase of treatment for ALL. Early recognition is very important to treat this potentially catastrophic yet treatable complication.

Entities:  

Keywords:  Acute lymphoblastic leukemia; Cortical vein thrombosis; L-asparaginase

Year:  2010        PMID： 23100993      PMCID： PMC3452943          DOI： 10.1007/s12288-010-0005-7

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


  5 in total

Review 1.  Thrombosis of the cerebral veins and sinuses.

Authors:  Jan Stam
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

2.  Thromboembolic complications associated with L-asparaginase therapy. Etiologic role of low antithrombin III and plasminogen levels and therapeutic correction by fresh frozen plasma.

Authors:  O Kucuk; H C Kwaan; W Gunnar; R M Vazquez
Journal:  Cancer       Date:  1985-02-15       Impact factor: 6.860

3.  Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia.

Authors:  R Elhasid; N Lanir; R Sharon; M Weyl Ben Arush; C Levin; S Postovsky; A Ben Barak; B Brenner
Journal:  Blood Coagul Fibrinolysis       Date:  2001-07       Impact factor: 1.276

4.  Altered von Willebrand factor molecule in children with thrombosis following asparaginase-prednisone-vincristine therapy for leukemia.

Authors:  C H Pui; C M Chesney; J Weed; C W Jackson
Journal:  J Clin Oncol       Date:  1985-09       Impact factor: 44.544

5.  Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration.

Authors:  Ulrike Nowak-Göttl; Elvira Ahlke; Gudrun Fleischhack; Dirk Schwabe; Rosmarie Schobess; Christiane Schumann; Ralf Junker
Journal:  Blood       Date:  2002-11-27       Impact factor: 22.113
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.